Indivior (INDV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
Achieved strong financial results in 2025, with net revenue up 4% to $1.24B and SUBLOCADE revenue up 13% to $856M, driving a 30x increase in GAAP net income to $210M and a 20% rise in adjusted EBITDA to $428M.
Completed Phase I of the Indivior Action Agenda and entered Phase II, focusing on accelerating SUBLOCADE growth and operational efficiency in 2026.
Resolved a legacy DOJ matter, strengthening the balance sheet and enabling a $400M share repurchase program.
Transitioned to U.S. incorporation and Nasdaq listing, aligning governance and compensation practices with U.S. standards.
Voting matters and shareholder proposals
Shareholders will vote to elect eight directors for one-year terms, approve executive compensation (say-on-pay), select the frequency of say-on-pay votes, and ratify PwC as the independent auditor for 2026.
Board recommends voting for all director nominees, for annual say-on-pay votes, and for PwC's ratification.
Board of directors and corporate governance
Board consists of eight members, seven of whom are independent; led by an independent Chair with separate CEO and Chair roles.
Board committees include Audit, Compensation, Compliance & Ethics, Nominating & Corporate Governance, and Science, all with independent members.
Annual board and committee self-evaluations are conducted, and a majority voting policy is in place for director elections.
Stock ownership guidelines, anti-hedging/pledging, and a clawback policy are enforced.
Latest events from Indivior
- Key votes include director elections, executive pay, and auditor ratification for 2026.INDV
Proxy filing27 Mar 2026 - Record SUBLOCADE growth, margin gains, and a $400M share repurchase program set up further acceleration.INDV
Q4 202526 Feb 2026 - SUBLOCADE drives strong revenue and EBITDA growth, with 2026 set for further acceleration.INDV
Investor presentation26 Feb 2026 - Q3 2024 revenue up 13% and profit up 62%, led by SUBLOCADE and strong U.S. sales.INDV
Q3 202416 Feb 2026 - Q1 2025 revenue fell 6% as generic competition intensified; cost controls supported profit.INDV
Q1 202516 Feb 2026 - FY 2024 guidance cut, PERSERIS discontinued, $85m litigation settled; long-term targets intact.INDV
Investor Update3 Feb 2026 - Q2 2024 revenue up 8%, SUBLOCADE up 24%, $75m litigation provision, $100m buyback.INDV
Q2 20243 Feb 2026 - Addiction treatment growth accelerates with new products, pipeline advances, and U.S. market focus.INDV
Jefferies Global Healthcare Conference31 Jan 2026 - OUD treatment growth continues amid easing Medicaid headwinds and focused pipeline development.INDV
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026